Opko Health - Der nächste Blockbuster - Älteste Beiträge zuerst (Seite 12)

[faultcode]

OPKO Confirms Resumption of Common Stock Trading on Nasdaq --> geht wieder weiter: -8.6% z.Z.

http://investor.opko.com/news-releases/news-release-details/…

=>
...OPKO Health, Inc. (NASDAQ: OPK) is pleased to confirm that The Nasdaq Stock Market has lifted the trading suspension of OPKO’s shares.

As noted previously, OPKO and 19 other defendants, including Dr. Phillip Frost, its CEO and Chairman, were named in a Complaint filed on September 7 by the Securities and Exchange Commission (“SEC”). The Company will vigorously defend itself against these charges...


=> Angangsverluste teilweise wieder gutgemacht

[tomsylver]

Statement von Phillip Frost

MIAMI--(BUSINESS WIRE)--Dr. Phillip Frost today issued the following statement regarding the lawsuit filed by the Securities and Exchange Commission on September 7, 2018:

“I was stunned by the SEC’s lawsuit and deny the allegations it contains against me. It was particularly disturbing that the SEC departed from its own longstanding practice of providing advance notice and a meaningful opportunity to address their questions in advance of filing an action.

“The allegations against me are belied by common sense, my history of supporting promising scientific technology, and the facts. I invested in two of the entities identified in the complaint. These investments were made because I understood the entities presented promising medical developments and a real opportunity to deliver value for shareholders. I remain a significant long-term shareholder in both companies."

“Nothing is more important to me than my integrity and I am deeply proud of the role I have played over many decades in developing medicines and diagnostic tools that have improved many lives. I intend to fight the charges that have been brought against me and will fight to clear my name.”

[faultcode]

Antwort auf Beitrag Nr.: 58.704.126 von faultcode am 14.09.18 20:12:18

heute +15%

after hours nochmal +2.5% z.Z. hinterher

nb: gegen den NBI mit heute ~-1.3% -- also gegen den Markt eigentlich (obwohl OPK zu sehr im "Sondermodus" z.Z. läuft - und auch noch längere Zeit laufen wird)


=> die Aktie "will nach oben":




=> die nächsten Widerstände:
• ~USD4.9
• ~USD6.25

[faultcode]

Antwort auf Beitrag Nr.: 58.723.159 von faultcode am 18.09.18 00:03:08

dieser feinsinnige und gemächliche Aufwärtstrend ist mir jetzt erst aufgefallen:

[tomsylver]

Billionaire Frost retires as Ladenburg chairman amid SEC lawsuit

Billionaire Frost retires as Ladenburg chairman amid SEC lawsuit

By Brian Bandell – Senior Reporter, South Florida Business Journal
Sep 20, 2018,

Billionaire Phillip Frost has retired as chairman and a board member of Ladenburg Thalmann Financial Services as he leads Opko Health and deals with a Securities and Exchange Commission lawsuit.

Miami-based financial services firm Ladenbrg (NYSE: LTS) named President and CEO Richard Lampen as chairman and appointed Executive VP and COO Adam Malamed as a board member.

According to Yahoo! Finance, Frost controls 67.3 million shares of LTS, or about one-third of its outstanding shares.

“I have decided to retire from the Ladenburg board and will concentrate my efforts on Opko Health and my philanthropic interests,” Frost said in a statement. “As a long-term shareholder, I am confident in Ladenburg’s outlook and look forward to its continued growth and success.”

On Sept. 7, the SEC filed a complaint against Frost and nine other men, plus 10 companies, including Miami-based Opko (Nasdaq: OPK), accusing them of participating in a $27 million penny stock fraud. In a scheme allegedly orchestrated by Barry C. Honig of Boca Raton, the group engaged in a “pump-and-dump” scheme to manipulate the prices of three penny stocks, according to the complaint.

Frost denied wrongdoing in a statement on Sept. 14.

The complaint did not mention Ladenburg. However, shares of LTS fell sharply after the SEC lawsuit was announced. Ladenburg works on many public offerings and issues analyst reports on stocks. The SEC is its main regulatory body.

“We thank Phil for his service to Ladenburg and its shareholders over the past 14 years,” Lampen said. “Ladenburg would not be where it is today without his many contributions, and his presence in the boardroom will be sorely missed.”

Frost remains a board member of Grove Bank & Trust. The Frost family has been among the biggest donors to the University of Miami, the Frost Museum of Science in Miami, Mount Sinai Medical Center, and Florida International University’s art museum.

[faultcode]

Antwort auf Beitrag Nr.: 58.738.567 von faultcode am 19.09.18 14:45:32

-11.5% wg. Guardant Health IPO

Guardant Health IPO: 5 things to know about the startup that wants to detect cancer early
https://www.marketwatch.com/story/guardant-health-ipo-5-thin…

=> halte ich - mal wieder - für übertrieben:

There are also companies working in early cancer detection, including Grail and Natera Inc., and ones that perform genomic analyses of tissue biopsies, like Opko Health’s Bio-Reference Laboratories Inc., Laboratory Corporation of America and Quest Diagnostics.

...

...denn weiter unten:

Though Guardant is selling liquid biopsy tests, they haven’t been approved by the Food and Drug Administration.

Instead, they are being sold as “laboratory developed tests,” a designation that was once for tests made and used by a single laboratory but has expanded dramatically.

Critics say that the category serves as a loophole, letting companies evade regulatory scrutiny — so much so that the FDA has said it wants to change the policy.

Guardant, notably, said it has invested “heavily” in clinical studies, including 80 peer-reviewed publications for its flagship Guardant360 test, according to its prospectus....

[faultcode]

Antwort auf Beitrag Nr.: 58.819.049 von faultcode am 28.09.18 00:33:58

=> hab hier noch mal ne kleine Schippe nachgelegt...

[tomsylver]

OPKO and OPKO's CEO and Chairman, Dr. Phillip Frost, Announce Proposed Resolution of SEC Action

OPKO Health and OPKO's CEO and Chairman, Dr. Phillip Frost, Announce Proposed Resolution of SEC Action
Frost to continue as CEO and Chairman of OPKO

MIAMI, Dec. 27, 2018 /PRNewswire/ -- In a settlement, subject to court approval, OPKO Health, Inc. (NASDAQ: OPK) and OPKO's CEO and Chairman, Dr. Phillip Frost, have agreed with the Securities and Exchange Commission to resolve the action brought against them in SEC v. Honig et al., 18 Civ. 08175 (S.D.N.Y).

Source: OPKO Health, Inc.

"We have reached agreement with the SEC that will end a potentially expensive, contentious and time-consuming litigation and I am happy that we can focus on an exciting and productive 2019 for OPKO Health," said Dr. Frost.

Without admitting or denying the SEC's allegations, OPKO agreed to an injunction from certain violations of the Securities Exchange Act of 1934 (the "Exchange Act"); a $100,000 penalty; and will perform certain undertakings related to the Exchange Act. Dr. Frost agreed, without admitting or denying the SEC's allegations, to injunctions from certain violations of the Securities Act of 1933 and the Exchange Act; approximately $5.5 million in penalty, disgorgement, and prejudgment interest; and a prohibition, with certain exceptions, from trading in penny stocks.

Dr. Frost will continue to serve as OPKO's CEO and Chairman.

[tomsylver]

OPKO Appoints Jon R. Cohen, Executive Chairman of BioReference Laboratories; Geoff Monk promoted to President

OPKO Health Appoints Jon R. Cohen, M.D. Executive Chairman of BioReference Laboratories
Geoff Monk promoted to President

MIAMI, Jan. 07, 2019 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced the appointment of Jon R. Cohen, M.D. as Executive Chairman of BioReference Laboratories. BioReference, with its GeneDx unit, is the third largest clinical laboratory in the United States.

OPKO also announced the promotion of Geoff Monk to President of BioReference. Mr. Monk joined BioReference as General Manager in May 2018 and will report to Dr. Cohen.

Dr. Cohen brings to OPKO more than 30 years of healthcare experience as a seasoned strategic leader with extensive and diverse experience; his track record of expanding existing business and developing new ventures, while dealing effectively with the payor universe, is well recognized in the diagnostics industry. Dr. Cohen served for nearly a decade as a senior executive at Quest Diagnostics, most recently as Senior Vice President and Group Executive – Diagnostic Solutions. During his tenure with Quest, his business responsibilities included the hospital reference business, cancer services, pathology services, sports diagnostics and professional laboratory services, Quest’s comprehensive offerings to hospitals and health systems.

“Jon is a highly regarded healthcare strategist with a tremendous track record of commercial success in the diagnostics industry, and we at OPKO are delighted to have Jon assume this new leadership position,” stated Phillip Frost, M.D., Chairman and Chief Executive Officer of OPKO Health. “Geoff Monk, during the short time he has been with BioReference, has proven to be a superb executive who has earned the respect and admiration of his colleagues. Under Geoff’s leadership, BioReference has made significant progress in achieving greater operating efficiency, which has positioned us for profitable growth as we head into 2019. We believe OPKO’s diagnostic business has a very bright future under the strong leadership of these outstanding professionals,” added Dr. Frost.

Commenting on his appointment, Dr. Cohen said, “The clinical diagnostics industry is changing at a rapid pace and must work with numerous stakeholders who often have conflicting agendas. That said, BioReference and GeneDx are well positioned with a broad and growing offering of established routine tests and next-generation genetic tests, and an unwavering commitment to customer service. We have the critical mass to compete effectively and will pursue market opportunities in a thoughtful, yet aggressive manner.”

Prior to joining Quest, Dr. Cohen was a Managing Director, Health Industries Services at PricewaterhouseCoopers, with specific expertise in quality of care standards, health information technology, physician recruitment strategies, health system network integration and merger strategies. Earlier he served as Chief Medical Officer at North Shore-Long Island Jewish Health System (Northwell Health) and as Chief Policy Advisor to New York Governor David A. Paterson. A vascular surgeon, Dr. Cohen completed his residency in general surgery at New York Presbyterian Hospital/Weill Cornell Medical Center and a fellowship in vascular surgery at the Brigham and Women's Hospital at Harvard Medical School. He holds a B.S. degree from the University of Miami and an M.D. degree from the University of Miami School of Medicine.

About BioReference Laboratories, Inc.

BioReference Laboratories is the nation’s third largest clinical laboratory, offering a comprehensive array of laboratory testing services to be utilized by physicians, clinics, and hospitals in the detection, diagnosis, evaluation, monitoring and treatment of disease. The company operates a network of 11 laboratory locations across the U.S., nearly 200 Patient Service Centers and a courier dispatch service to manage specimen pickup. BioReference provides state-of-the-art connectivity solutions including the ability to interface with all electronic medical records (EMRs), and data analytics to help improve office efficiency. For more information, visit www.bioreference.com.

About OPKO Health, Inc.

OPKO Health is a diversified healthcare company. In diagnostics, its BioReference Laboratories is the nation's third largest clinical laboratory; GeneDx is a rapidly growing genetic testing business; the 4Kscore® prostate cancer test is used to confirm an elevated PSA to help decide about next steps such as prostate biopsy; Claros® 1 is a point-of-care diagnostics platform with PSA and testosterone as the most advanced in development. In our pharmaceutical pipeline, RAYALDEE is our first pharmaceutical product to be marketed. OPK88003, a once-weekly oxyntomodulin for type 2 diabetes and obesity in Phase 2 clinical trials, is among a new class of GLP-1 – glucagon receptor dual agonists. OPK88004, a SARM (selective androgen receptor modulator) for treating various urology conditions, is in clinical trials. The Company’s most advanced product utilizing its CTP technology, a once-weekly human growth hormone for injection, is in Phase 3 trials, and is partnered with Pfizer. OPKO also has research, development, production and distribution facilities abroad. More information is available at www.opko.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning, including statements about expectations for BioReference and GeneDx, our ability to achieve operating efficiencies, and expected profitability and growth in 2019, as well as other non-historical statements about our expectations, beliefs or intentions. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in our Annual Reports on Form 10-K filed and to be filed with the Securities and Exchange Commission and in our other filings with the Securities and Exchange Commission. Forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.

Contacts:

LHA Investor Relations
Miriam Weber Miller, 212-838-3777
[e-mail]
or
Bruce Voss, 310-691-7100
[e-mail]

opko.jpg

[tomsylver]

Barrington Research: With SEC Litigation Settled, Opko Health Should Outperform

Barrington Research: With SEC Litigation Settled, Opko Health Should Outperform

January 9, 2019 (Benzinga)

Opko Health Inc. (NASDAQ: OPK) lost around 57 percent over the span of a few months after the SEC named the company as a defendant in a lawsuit alleging a "pump-and-dump" stock trading by CEO and Chairman Dr. Phil Frost.

The conclusion of the litigation — which ended with the company agreeing to pay a $100,000 penalty and Frost paying a $5-million fine — has been positive for the company’s shares, which have rallied more than 40 percent since December, according to Barrington Research.

The Analyst

Analyst Michael Petusky maintains an Outperform rating on Opko Health with a $7 price target.

The Thesis

With the SEC issue behind it, Opko Health can now fully focus on growth, improving operations and making progress in its pre-commercial product pipeline, Petusky said in a Wednesday note.

Opko Health has named Jon Cohen as executive chairman and Geoff Monk as president of its BioReference Laboratories business, which has been a major contributor to the company’s financial results.

While both moves appear positive, “we are particularly encouraged by Mr. Monk’s promotion given the fact that he has been charged with driving improvement in BRL’s operations since he was hired in May 2018,” the analyst said.

Opko Health could generate revenue of $239.1 million in Q4, with BRL contributing approximately $190.3 million, according to Barrington. The company’s EPS for the quarter is projected at a negative 7 cents per share, Petusky said.